NY A08502

Amends insurance law and social services law to require health insurance policies and Medicaid to cover "biomarker precision medical testing" for diagnosis, treatment, management, or ongoing monitoring of insured persons' diseases or conditions.

Expands coverage criteria to include peer-reviewed literature and scientific studies published in nationally recognized medical journals, in addition to FDA approvals, Medicare coverage determinations, and clinical practice guidelines.

Removes the requirement that tests demonstrate "clinical utility" and replaces it with language recognizing "efficacy and appropriateness" of biomarker precision medical testing.

Requires coverage to be provided in a manner that limits care disruptions, including reducing the need for multiple biopsies or biospecimen samples.

Delays the effective date of the 2023 biomarker testing coverage law from April 1, 2024 to January 1, 2025, applying to policies and contracts issued, renewed, modified, or amended on or after that date.